Usefulness of Dried Blood Spots (DBS) to perform hepatitis C virus genotyping in drug users in Senegal
© 2015 Wiley Periodicals, Inc..
The aim of this pilot study was to analyze the Hepatitis C Virus (HCV) genotypes circulating in Senegal among Drug User (DUs), using Dried Blood Spots (DBS) as RNA source for molecular assays. Heroin and/or cocaine users (n = 506) were recruited in Dakar from April to July 2011, using a Respondent Driven Sampling (RDS) method. DBS preparation consisted of five drops of whole blood from finger applied to a Whatman paper card. HCV infection was screened by the detection of anti-HCV antibodies, using a rapid immune-chromatographic test. HCV RNA was quantified on anti-HCV positive DBS, using the Abbott RealTime HCV® Genotyping was performed on DBS with detectable viral load with Versant® HCV Genotype 2.0 Assay (LiPA) and Abbott RealTime HCV Genotype II assay®. Among the 506 participants, 120 were tested as positive for anti-HCV antibodies and their samples were analyzed for HCV RNA viral load and genotype. Out of the 120 DBS tested, HCV RNA was detected on 25 (20.8%). The median viral load was 15,058 IU/ml (ranging from 710 to 766,740 IU/ml). All positive DBS were suitable for the genotyping assay, that showed a predominance of genotype 1 (21/25) including 16 genotypes 1a and 5 genotypes 1b. HCV genotype 1 prevails in a DU population in Dakar. DBS could be useful for HCV RNA genotyping, but optimal storage conditions should required avoiding RNA impairment. Acknowledging this limitation, DBS could be a great interest for detecting and genotyping HCV viremic patients. J. Med. Virol. 89:484-488, 2017. © 2015 Wiley Periodicals, Inc.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:89 |
|---|---|
| Enthalten in: |
Journal of medical virology - 89(2017), 3 vom: 15. März, Seite 484-488 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ndiaye, O [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
DBS |
|---|
| Anmerkungen: |
Date Completed 07.09.2017 Date Revised 10.12.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.24460 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM255910223 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM255910223 | ||
| 003 | DE-627 | ||
| 005 | 20231224175508.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.24460 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0853.xml |
| 035 | |a (DE-627)NLM255910223 | ||
| 035 | |a (NLM)26705258 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ndiaye, O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Usefulness of Dried Blood Spots (DBS) to perform hepatitis C virus genotyping in drug users in Senegal |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.09.2017 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2015 Wiley Periodicals, Inc. | ||
| 520 | |a The aim of this pilot study was to analyze the Hepatitis C Virus (HCV) genotypes circulating in Senegal among Drug User (DUs), using Dried Blood Spots (DBS) as RNA source for molecular assays. Heroin and/or cocaine users (n = 506) were recruited in Dakar from April to July 2011, using a Respondent Driven Sampling (RDS) method. DBS preparation consisted of five drops of whole blood from finger applied to a Whatman paper card. HCV infection was screened by the detection of anti-HCV antibodies, using a rapid immune-chromatographic test. HCV RNA was quantified on anti-HCV positive DBS, using the Abbott RealTime HCV® Genotyping was performed on DBS with detectable viral load with Versant® HCV Genotype 2.0 Assay (LiPA) and Abbott RealTime HCV Genotype II assay®. Among the 506 participants, 120 were tested as positive for anti-HCV antibodies and their samples were analyzed for HCV RNA viral load and genotype. Out of the 120 DBS tested, HCV RNA was detected on 25 (20.8%). The median viral load was 15,058 IU/ml (ranging from 710 to 766,740 IU/ml). All positive DBS were suitable for the genotyping assay, that showed a predominance of genotype 1 (21/25) including 16 genotypes 1a and 5 genotypes 1b. HCV genotype 1 prevails in a DU population in Dakar. DBS could be useful for HCV RNA genotyping, but optimal storage conditions should required avoiding RNA impairment. Acknowledging this limitation, DBS could be a great interest for detecting and genotyping HCV viremic patients. J. Med. Virol. 89:484-488, 2017. © 2015 Wiley Periodicals, Inc | ||
| 650 | 4 | |a Evaluation Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DBS | |
| 650 | 4 | |a HCV | |
| 650 | 4 | |a Senegal | |
| 650 | 4 | |a drug users | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Gozlan, J |e verfasserin |4 aut | |
| 700 | 1 | |a Diop-Ndiaye, H |e verfasserin |4 aut | |
| 700 | 1 | |a Sall, A S |e verfasserin |4 aut | |
| 700 | 1 | |a Chapelain, S |e verfasserin |4 aut | |
| 700 | 1 | |a Leprêtre, A |e verfasserin |4 aut | |
| 700 | 1 | |a Maynart, M |e verfasserin |4 aut | |
| 700 | 1 | |a Gueye, M |e verfasserin |4 aut | |
| 700 | 1 | |a Lo, G |e verfasserin |4 aut | |
| 700 | 1 | |a Thiam, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ba, I |e verfasserin |4 aut | |
| 700 | 1 | |a Lacombe, K |e verfasserin |4 aut | |
| 700 | 1 | |a Girard, P M |e verfasserin |4 aut | |
| 700 | 1 | |a Mboup, S |e verfasserin |4 aut | |
| 700 | 1 | |a Kane, C T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 89(2017), 3 vom: 15. März, Seite 484-488 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:89 |g year:2017 |g number:3 |g day:15 |g month:03 |g pages:484-488 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.24460 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 89 |j 2017 |e 3 |b 15 |c 03 |h 484-488 | ||